Effects of ABB C3 on body fat and glucose metabolism in children and teens
Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents
This study tests if a new postbiotic blend called ABB C3 can help kids and teens aged 8 to 18 lose body fat and improve their metabolism over six months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 8 Years to 18 Years |
| Sex | All |
| Sponsor | Fundació Sant Joan de Déu Academic / other |
| Locations | 1 site (Barcelona) |
| Trial ID | NCT06309121 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of a postbiotic blend known as ABB C3 on reducing body fat and enhancing metabolic health in children and adolescents aged 8 to 18 years. It employs a randomized, double-blind design where participants are assigned to either the ABB C3 group or a placebo group for a duration of 3 months, during which body composition and blood markers will be monitored. Following this initial phase, all participants will have the option to continue with ABB C3 for an additional 3 months. The study aims to assess both the efficacy and safety of ABB C3 in improving health outcomes related to obesity.
Who should consider this trial
Good fit: Ideal candidates for this study are children and adolescents aged 8 to 18 years with obesity, defined as a BMI-SDS greater than 2.
Not a fit: Patients with chronic diseases affecting glucose or lipid metabolism, or those on medications that influence weight or appetite, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safe and effective method for reducing body fat and improving metabolic health in young individuals struggling with obesity.
How similar studies have performed: While the specific postbiotic ABB C3 may be novel, similar studies investigating postbiotics for obesity management have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 8- and 18-year-old * Obesity (BMI-SDS \> 2) Exclusion Criteria: * Antibiotic or pre/pro/postbiotic consumption 2 - 4 weeks prior to starting the study * Chronic diseases affecting glucose or lipid metabolism * Chronic medication affecting glucose or lipid metabolism, or inducing a pro-inflammatory state * History of bariatric surgery * Diabetes requiring insulin treatment * Severe intellectual disability * Pregnancy * Individuals taking medications that may alter appetite or weight, with a recent change in prescription within the last 3 months or anticipated changes during the 2 months of participation
Where this trial is running
Barcelona
- Hospital Sant Joan de Déu — Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Carles Lerin, PhD — Fundació Sant Joan de Deu
- Study coordinator: Marta Ramon Krauel, MD, PhD
- Email: marta.ramon@sjd.es
- Phone: (+34) 932804000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.